Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2013, Article ID 901253, 8 pages
Clinical Study

Adduct of Malondialdehyde to Hemoglobin: A New Marker of Oxidative Stress That Is Associated with Significant Morbidity in Preterm Infants

1Département de Néonatologie, CHU Angers, 49100 Angers, France
2Département de Néonatologie, Hôpital de la Croix Rousse, Hospices Civils de Lyon, 69004 Lyon, France
3Centre de Recherche en Nutrition Humaine Rhône-Alpes, Centre hospitalier Lyon-Sud, 69310 Pierrre Bénite, France
4Département de Biostatistique, Hospices Civils de Lyon, 69003 Lyon, France
5Université Claude Bernard Lyon I, 69100 Villeurbanne, France
6CNRS UMR5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique Santé, 69310 Pierre-Bénite, France
7Centre de Biologie Sud, UF Nutrition et Métabolisme, Centre hospitalier Lyon-Sud, Hospices Civils de Lyon, 69310 Pierrre Bénite, France

Received 8 February 2013; Revised 28 March 2013; Accepted 29 March 2013

Academic Editor: Kota V. Ramana

Copyright © 2013 Cécile Cipierre et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Preterm infants (PT) are particularly exposed to oxidative stress (OS), and a blood-sparing marker, the malondialdehyde adduct to hemoglobin (MDA-Hb), may be useful to accurately assess OS-related neonatal morbidity. In a prospective study, MDA-Hb concentrations were assessed in two groups of PT, one with and one without severe neonatal morbidity as estimated by a composite index of severe morbidity (ISM). All PT born in a single tertiary care NICU ( 32 weeks and birth weight  g) were consecutively included. MDA-Hb and blood glutathione (GSH) concentrations were measured by liquid chromatography-mass spectrometry during the first 6 weeks of life. Linear regressions and a multilevel model were fitted to study the relationship between MDA-Hb or GSH and ISM. Of the 83 PT (mean ± SD: weeks,  g), 21% presented severe neonatal morbidity. In the multivariate model, MDA-Hb concentrations were significantly higher in the ISM+ group than in the ISM– group during the first 6 weeks of life ( ). No significant difference in GSH concentrations was observed between groups ( ). MDA-Hb is a marker of interest for estimating oxidative stress in PT and could be useful to evaluate the impact of strategies to improve perinatal outcomes.